Strata Raised 2026 Guidance, but 60% Growth Only Matters if M&A Turns Into Lasting Profit

Raised 2026 guidance is the headline; durable earnings are the test

Strata's raised 2026 guidance is the headline, but it is only the start. Management lifted full-year revenue to $285 million to $295 million and adjusted EBITDA to $33 million to $35 million. The bigger question is whether acquired volume is translating into a more profitable operating base, not just a larger topline.

Q2 showed real operating demand. Revenue jumped 60.7% year over year to $72.5 million, adjusted EBITDA rose to $7.9 million, and the adjusted EBITDA margin improved to 10.9%. Most importantly, clinical revenue excluding Q2 acquisitions grew 15.1% sequentially, suggesting demand persisted after acquisition integration noise was stripped out.

The offset is clear: Strata still posted a net loss from continuing operations of $10.5 million, or 14.5% of revenue. The positive side is that cash generation improved, with $5.7 million of operating cash flow in the quarter. The next few quarters should show whether growth is becoming more durable.

Clinical demand improved beyond the acquisitions

Management's message was not just about a bigger guide. It was about showing that part of the growth engine is coming from operating demand, not only acquisition additions.

Sequential clinical growth points to underlying demand

Clinical revenue rose 22.6% sequentially, but the more useful measure is that clinical revenue excluding Q2 acquisitions grew 15.1% sequentially. That better isolates how the existing customer base is performing without the acquired book. The clearest bright spot was Transplant Clinical revenue up 23.8% sequentially, reinforcing the idea that the clinical platform remains the higher-value part of the model.

Statline relationships are a practical catalyst to watch

Strata also said it signed an agreement to take over Statline's transplant center organ placement customer relationships on a rolling basis over the next year. That is a useful watchpoint because it could add volume with more visibility than another sudden acquisition.

Q2 profitability improved, but integration risk still matters

The stronger parts of the quarter

Gross profit held up well alongside revenue. Strata generated $15.2 million of gross profit in Q2 and reported a 21.0% gross margin. That suggests the quarter was not just top-line expansion.

Clinical gross margin also improved, rising to 26.1% from 25.0% in Q1. That matters because it implies the higher-value part of the business is not getting diluted by growth. Combined with $5.7 million of operating cash flow, the quarter showed some real operating traction.

Logistics margin and net loss are still the drag

Logistics gross margin fell to 18.4%, down from 19.8% in Q1. That kind of slip usually points to pricing, mix, or integration friction, and it is the part of the quarter investors should not gloss over.

Strata still posted a $10.5 million net loss from continuing operations, or 14.5% of revenue. That keeps the central debate intact: if clinical strength and cash flow keep improving, the business has a credible foundation; if logistics drag persists, the profit story will take longer to validate.

Guidance hike shifts the debate toward execution

The key point now is simpler than the narrative around it. Once management raised the full-year target to $285 million to $295 million revenue and $33 million to $35 million adjusted EBITDA, the story stopped being about ambition and became about defense of that new bar.

What would reinforce the bull case

Bulls can point to 60.7% year-over-year revenue growth and the fact that management has already raised 2026 revenue guidance while also lifting adjusted EBITDA guidance. That combination matters because it suggests Strata is not just growing through M&A, but also expanding the earnings base.

What would weaken the thesis

The setup weakens if logistics margin slips again or if another guidance increase relies more on optimism than repeatable execution. A second consecutive quarter around the current 10.9% adjusted EBITDA margin would matter more than another bold topline headline, because it would show the acquired pieces are starting to function more like one operating model.